Aquestive Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aquestive Therapeutics (AQST).

Price Target Range — 10 Quarters

Analyst Consensus — 9 Analysts

1S.Buy

8Buy

Consensus RatingOutperform# Analysts9Avg. Consensus PT$10Upside to Avg. PT+157.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 24, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$10
Nov 7, 2025	Piper Sandler	David Amsellem	PT Raise	Overweight	$5→$8
Oct 9, 2025	JMP Securities	Jason Butler	PT Raise	Market Outperform	$9→$12
Sep 8, 2025	Oppenheimer	Francois Brisebois	PT Raise	Outperform	$7→$8
Jun 17, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$10
Jun 2, 2025	Oppenheimer	Andreas Argyrides	Assumes	Outperform	$15→$7
May 15, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$10
Apr 2, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$10
Mar 10, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$10
Mar 7, 2025	Lake Street	Thomas Flaten	PT Cut	Buy	$10→$8
Dec 20, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$10
Dec 17, 2024	Cantor Fitzgerald	Kristen Kluska	Initiate	Overweight	$17
Nov 11, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$10
Nov 6, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$10
Oct 25, 2024	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$12→$13
Oct 25, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$10
Oct 8, 2024	JMP Securities	Jason Butler	Maintained	Market Outperform	$9
Sep 30, 2024	JMP Securities	Jason Butler	Maintained	Market Outperform	$9
Sep 30, 2024	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$10→$12
Sep 30, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$9→$10

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:AQST) with a Buy and maintains $10 price target.

Benzinga Newsdesk

Bad News For Competitor Turns Into Big Win For ARS Pharma Stock

ARS Pharmaceuticals Inc. stock rose Friday as FDA identified deficiencies in rival Aquestive's application, delaying potential competition.

Vandana Singh

PRO
Piper Sandler Maintains Overweight on Aquestive Therapeutics, Raises Price Target to $8

Piper Sandler analyst David Amsellem maintains Aquestive Therapeutics (NASDAQ:AQST) with a Overweight and raises the price target from $5 to $8.

Benzinga Newsdesk

PRO
JMP Securities Maintains Market Outperform on Aquestive Therapeutics, Raises Price Target to $12

JMP Securities analyst Jason Butler maintains Aquestive Therapeutics (NASDAQ:AQST) with a Market Outperform and raises the price target from $9 to $12.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Aquestive Therapeutics, Raises Price Target to $8

Oppenheimer analyst Francois Brisebois maintains Aquestive Therapeutics (NASDAQ:AQST) with a Outperform and raises the price target from $7 to $8.

Benzinga Newsdesk

FDA Confirms Direct Review Path For Aquestive's Allergy Treatment

Aquestive's Anaphylm could become the first oral epinephrine for severe allergic reactions after the FDA set a 2026 decision date without panel review.

Vandana Singh

Aquestive Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Aquestive Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target

Bad News For Competitor Turns Into Big Win For ARS Pharma Stock

PRO
Piper Sandler Maintains Overweight on Aquestive Therapeutics, Raises Price Target to $8

PRO
JMP Securities Maintains Market Outperform on Aquestive Therapeutics, Raises Price Target to $12

PRO
Oppenheimer Maintains Outperform on Aquestive Therapeutics, Raises Price Target to $8

FDA Confirms Direct Review Path For Aquestive's Allergy Treatment

People Also Watch

People Also Watch

Aquestive Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Aquestive Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target

Bad News For Competitor Turns Into Big Win For ARS Pharma Stock

PROPiper Sandler Maintains Overweight on Aquestive Therapeutics, Raises Price Target to $8

PROJMP Securities Maintains Market Outperform on Aquestive Therapeutics, Raises Price Target to $12

PROOppenheimer Maintains Outperform on Aquestive Therapeutics, Raises Price Target to $8

FDA Confirms Direct Review Path For Aquestive's Allergy Treatment

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target

PRO
Piper Sandler Maintains Overweight on Aquestive Therapeutics, Raises Price Target to $8

PRO
JMP Securities Maintains Market Outperform on Aquestive Therapeutics, Raises Price Target to $12

PRO
Oppenheimer Maintains Outperform on Aquestive Therapeutics, Raises Price Target to $8